Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, executive pay and an increase to the share reserve under its stock incentive plan.
Stockholders will elect four Class II directors to terms ending in 2029, vote on ratifying Ernst & Young LLP as independent auditor for 2026, cast an advisory say-on-pay vote on 2025 compensation for named executive officers, and decide on expanding the Amended and Restated Stock Incentive Plan. The company highlights a turnaround in 2025, with total revenue of $742.9 million versus $1,043.6 million in 2024, net income of $52.6 million after a prior-year loss, and adjusted EBITDA of $205.0 million.
The proxy describes a heavily independent, skills-diverse board, detailed committee structure, and pay-for-performance compensation design emphasizing variable and equity-based pay. It also discloses major institutional holders and shows that executives and directors collectively beneficially own 6.0% of outstanding common stock as of March 6, 2026.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.
Emergent BioSolutions Inc. reported that President and CEO Joseph C. Papa received an award of employee stock options covering 252,194 shares on March 3, 2026, at an exercise price of $0.00 per share. These options vest in three equal installments beginning the day prior to each anniversary of the grant date.
On March 5, 2026, 37,055 shares of common stock were withheld and disposed of to cover taxes tied to the vesting and settlement of performance stock units at a price of $8.44 per share, leaving Papa with 305,445 common shares directly owned.
FOWLER JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. director John D. Fowler Jr reported an equity award of 5,006 shares of common stock in the form of restricted stock units. The units were granted at a reference value of $8.99 per share and were issued under the company’s Stock Incentive Plan.
These 5,006 restricted stock units vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming he continues serving the company. Each unit represents the right to receive one share of Emergent BioSolutions common stock, and Fowler now directly holds 5,006 shares following this grant.
Emergent BioSolutions Inc. director John D. Fowler Jr filed an initial ownership report on Form 3 showing he directly beneficially owns no shares of the company’s common stock as of the reported date. The filing does not report any buy or sell transactions, only a zero balance.
Emergent BioSolutions SVP, R&D, CMO Simon C. Lowry reported two equity compensation transactions. On March 5, 2026, 10,636 shares of common stock were disposed of at $8.44 per share to cover taxes tied to vesting and settlement of restricted stock units, leaving 77,803 shares held directly. On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, with the options vesting in three equal installments beginning the day before each anniversary of the grant date, increasing his directly held options to 147,833.
Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions. On March 5, 2026, 9,493 shares of common stock were disposed of at $8.44 per share to cover taxes tied to restricted stock unit vesting, leaving him with 87,188 shares of common stock held directly.
On March 3, 2026, he received a grant of 44,834 employee stock options, increasing his directly held options to 259,545. The grant is scheduled to vest in three equal installments beginning on the day prior to each anniversary of the grant date.
Emergent BioSolutions Inc. reported insider equity activity by SVP and General Counsel Jessica Perl. She received a grant of 46,702 employee stock options at an exercise price of $0.00 per option on common stock. According to a footnote, these options vest in three equal installments beginning on the day prior to the anniversary date of the grant.
On a separate date, 6,465 shares of common stock were disposed of in a tax-withholding disposition at $8.44 per share, with a footnote explaining the shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units. Following these transactions, Perl directly owned 61,004 common shares and held 142,647 stock options.
Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported two equity compensation transactions. On March 5, 2026, 9,397 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, leaving him with 66,681 common shares directly held.
On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, increasing his directly held options to 254,948. The options vest in three equal installments beginning on the day prior to the anniversary date of the grant.
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported routine equity compensation and related tax withholding. On March 3, he acquired 72,856 employee stock options at an exercise price of $0.00 per share as a grant that vests in three equal installments beginning the day prior to each anniversary of the grant date. On March 5, 23,650 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, rather than through an open-market sale. After these transactions, he held 215,367 shares of common stock and 557,346 stock options directly.